Researchers estimate that more than 30 million people in the U.S. and eight percent of children, have a food allergy. Many are at risk for life-threatening anaphylaxis, underscoring the urgent need for new therapies and diagnostics to accurately diagnose and manage patients living with food allergies.
Yet, current food allergy diagnostics have low specificity, contributing to the overdiagnosis of as many as 60 percent of patients. AllerGenis has developed its technology using data-driven machine learning and innovative multiplex immunoassay technology to more precisely diagnose and monitor patients with food allergies. It will be one of the first non-oncologic, precision medicine tools to help providers better diagnose, assess, and manage patients with food allergies.
At AllerGenis, our mission is to bring precision diagnostics to market with an enhanced capability to safely identify, diagnose, and monitor patients throughout the natural history of their allergic disease.